GUJTHEM430.00

Gujarat Themis Biosyn Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersRPGLIFEGUFICBIOORCHPHARMAUNICHEMLABFDCIOLCPMOREPENLABINNOVACAPMcap ₹4,685 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations150.8165.8
Other Income2.42.4
Total Income153.2168.3
Expenses
+ Cost of Materials Consumed25.830.4
+ Changes in Inventories-1.3-9.0
+ Employee Benefit Expense12.616.5
+ Finance Costs0.42.9
+ Depreciation & Amortisation5.412.9
+ Other Expenses44.852.4
Total Expenses87.7106.2
EBITDA68.875.5
EBIT63.562.6
Profit
PBT before Exceptional Items65.562.1
Pretax Income65.562.1
+ Current Tax16.510.8
+ Deferred Tax0.34.6
Tax Expense16.815.4
Net Income48.846.7
+ Net Income — Continuing Ops48.846.7
+ Other Comprehensive Income0.10.0
Total Comprehensive Income48.846.7
Per Share
Basic EPS4.480.00
Diluted EPS4.480.00
Other Comprehensive Income — detail
+ Other Comprehensive Income0.10.0
+ Items NOT to be Reclassified to P&L0.10.0
+ Tax on Items NOT to be Reclassified0.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations4.480.00
Diluted EPS — Continuing Operations4.480.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit126.3144.4
Gross Margin %83.7587.09
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)65.562.1
Net Income Adj (tax-effected)48.846.7
EPS Adj4.480.00
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.00
Paid Up Equity Capital10.910.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.